The feasibility and efficacy of gonadotropin-releasing hormone agonists for prevention of chemotherapy induced ovarian failure in patient with gynecological malignancies.
10.5468/ogs.2014.57.6.478
- Author:
Chan Yong PARK
1
;
Sun Young JUNG
;
Kwang Beom LEE
;
Sun Hye YANG
Author Information
1. Department of Obstetrics and Gynecology, Gil Hospital, Gachon University of Medicine and Science, Incheon, Korea. leekwbm@gilhospital.com
- Publication Type:Original Article
- Keywords:
Adjuvant chemotherapy;
Fertility preservation;
Gonadotropin releasing hormone agonist;
Ovarian neoplasms;
Uterine cervical neoplasms
- MeSH:
Chemotherapy, Adjuvant;
Drug Therapy*;
Female;
Fertility Preservation;
Follicle Stimulating Hormone;
Follow-Up Studies;
Gonadotropin-Releasing Hormone*;
Humans;
Ovarian Neoplasms;
Ovary;
Pregnancy;
Primary Ovarian Insufficiency;
Uterine Cervical Neoplasms
- From:Obstetrics & Gynecology Science
2014;57(6):478-483
- CountryRepublic of Korea
- Language:English
-
Abstract:
OBJECTIVE: To assess the effects of a gonadotropin-releasing hormone agonist (GnRH-a) depot (Leuprolide acetate) in women with gynecologic cancer receiving chemotherapy while taking a continuous add-back on the prevention of premature ovarian failure. METHODS: Fourteen premenopausal patients with gynecological malignancies who had undergone conservation of ovaries surgery received a GnRH-a depot plus add-back until chemotherapy was completed. Four weeks thereafter, a hormonal profile (follicle stimulating hormone) was measured. RESULTS: The mean follicle stimulating hormone level was 15.8 IU/L. All patients exhibited a restoration of ovarian failure during follow-up. One patient became pregnant during the follow-up period. CONCLUSION: In the short term, GnRH-a appears to protect ovarian function and ability to achieve pregnancy following chemotherapy. The result of our study needs further elucidation in a large randomized controlled trial.
